根据美国证券交易委员会(SEC)最新文件披露，生物材料公司Nexgel, Inc.已达成一项价值1330万美元的资产收购协议。该交易标的为细胞疗法企业Celularity的部分业务资产。
收购方案显示，Nexgel将支付830万美元现金，并发行面值500万美元的可转换票据完成此次收购。可转换票据作为一种混合型融资工具，赋予持有者未来将其转换为公司股权的权利。
这笔交易标志着Nexgel在生物医学材料领域的战略扩张。通过整合Celularity的先进细胞技术，Nexgel有望增强其在 regenerative medicine（再生医学）领域的核心竞争力。
SEC文件未披露可转换票据的具体转换条款及交易完成时间表。市场关注此次收购将对Nexgel财务状况和股价表现产生的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.